Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh, Elad; Deroma, Laura; Bembi, Bruno; Deegan, Patrick; Hollak, Carla; Weinreb, Neal J; Cox, Timothy M.
Cochrane Database Syst Rev
; (3): CD010324, 2015 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-25812601
Miglustat as a therapeutic agent: prospects and caveats.
Efficacy of miglustat in Niemann-Pick C disease: a single centre experience.
Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Migalastat: First Global Approval.
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial.
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
Fabry Nephropathy: An Evidence-Based Narrative Review.